BIOMAT Database Logo BIOMAT Database Logo

Evaluation of VP-16-213, cyclophosphamide, doxorubicin, and cisplatin (V-CAP) in advanced large cell lung cancer. 1981

R T Eagan, and S Frytak, and W C Nichols, and J N Ingle, and E T Creagan, and L K Kvols, and D T Coles

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010166 Palliative Care Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed) Palliative Treatment,Palliative Supportive Care,Palliative Surgery,Palliative Therapy,Surgery, Palliative,Therapy, Palliative,Care, Palliative,Palliative Treatments,Supportive Care, Palliative,Treatment, Palliative,Treatments, Palliative
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation

Related Publications

R T Eagan, and S Frytak, and W C Nichols, and J N Ingle, and E T Creagan, and L K Kvols, and D T Coles
Cisplatin plus VP 16-213 in advanced ovarian carcinoma.
June 1988, Gynecologic oncology,
R T Eagan, and S Frytak, and W C Nichols, and J N Ingle, and E T Creagan, and L K Kvols, and D T Coles
Adriamycin, cyclophosphamide, and etoposide (VP-16-213) in extensive-stage small cell lung cancer.
December 1984, American journal of clinical oncology,
R T Eagan, and S Frytak, and W C Nichols, and J N Ingle, and E T Creagan, and L K Kvols, and D T Coles
VP 16-213 (VP 16) and cyclophosphamide in the treatment of primitive lung cancer in phase M 1.
January 1979, Cancer,
R T Eagan, and S Frytak, and W C Nichols, and J N Ingle, and E T Creagan, and L K Kvols, and D T Coles
VP-16-213 and cyclophosphamide in small cell lung cancer: a long-term followup report.
January 1979, Cancer treatment reports,
R T Eagan, and S Frytak, and W C Nichols, and J N Ingle, and E T Creagan, and L K Kvols, and D T Coles
A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
March 1991, Cancer treatment reviews,
R T Eagan, and S Frytak, and W C Nichols, and J N Ingle, and E T Creagan, and L K Kvols, and D T Coles
The role of combination cyclophosphamide, doxorubicin and cisplatin (CAP) chemotherapy in advanced non-small-cell lung cancer.
August 1987, Tumori,
R T Eagan, and S Frytak, and W C Nichols, and J N Ingle, and E T Creagan, and L K Kvols, and D T Coles
VP-16 plus cyclophosphamide in the treatment of advanced lung cancer.
February 1983, Cancer,
R T Eagan, and S Frytak, and W C Nichols, and J N Ingle, and E T Creagan, and L K Kvols, and D T Coles
Cisplatin plus VP-16 in small-cell lung cancer.
September 1986, Seminars in oncology,
R T Eagan, and S Frytak, and W C Nichols, and J N Ingle, and E T Creagan, and L K Kvols, and D T Coles
Unchanged pharmacokinetics of VP-16-213 (etoposide, NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide.
June 1987, European journal of cancer & clinical oncology,
R T Eagan, and S Frytak, and W C Nichols, and J N Ingle, and E T Creagan, and L K Kvols, and D T Coles
Oral VP-16-213 in advanced bronchogenic carcinoma.
September 1981, Thorax,
Copied contents to your clipboard!